Clinical trials: Vinorelbine
Low-grade Glioma
Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas
The purpose of this study is to investigate whether weekly Vinorelbine treatment can shrink or slow the growth of pediatric low-grade gliomas that have either returned or are continuing to grow.
- Trial name
- NCT01497860
- Testing
- Vinorelbine
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Eugene Hwang
Advanced Non-Small Cell Lung Cancer
The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer
The purpose of this study is to compare the overall survival of patients with advanced non small cell lung cancer treated with docetaxel as single therapy versus docetaxel in combination with either gemcitabine or vinorelbine or…
- Trial name
- DISTAL-2 (NCT00345059)
- Testing
- docetaxel, vinorelbine, gemcitabine
- Where
- 24 sites in Italy
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute, Naples
Non-Small Cell Lung Cancer
A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy
This Phase III, global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody) compared with a single agent…
- Trial name
- IPSOS (NCT03191786)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Vinorelbine, Gemcitabine
- Where
- 91 sites in Argentina, Belgium and 22 more
- Volunteers
- 453 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Carcinoma, Metastatic Breast Cancer
Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)
The purpose of this non-interventional study is to collect data on efficacy and toxicity of the use of Navelbine ORAL in daily routine in Germany (especially after availability of an 80mg capsule).
- Trial name
- NCT00890903
- Where
- Germany
- Volunteers
- 62 people
- Sponsor
- Pierre Fabre Pharma GmbH
Breast Cancer
Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer
This is a randomized, double-blind multicenter Phase III study for evaluating the efficacy of neoadjuvant Navelbine plus trastuzumab and Pertuzumab versus Docetaxel plus trastuzumab and Pertuzumab given as neoadjuvant treatment…
- Trial name
- NCT04665986
- Testing
- Navelbine, Docetaxel
- Volunteers
- 50 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Breast Cancer
Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine
The investigators hypothesize that the administration of Toripalimab (anti-PD-1 antibody, JS001) combined to metronomic Vinorelbine may be an interesting therapeutic option for female patients with HER2- metastatic breast cancer.
- Trial name
- NCT04389073
- Testing
- Vinorelbine 40mg, Toripalimab 240mg, Bevacizumab 5 mg/kg
- Where
- 2 sites in China
- Volunteers
- 138 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer
Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of anlotinib combined with vinorelbine in the treatment of HER2- advanced breast cancer.
- Trial name
- NCT05296577
- Testing
- anlotinib and vinorelbine, Vinorelbine injection
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Henan Cancer Hospital
Non-small Cell Lung Cancer Stage III
Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation
This study is to compare 2-year Disease Free Survival Rate (DFSR) in post radical operation IIIA Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) 19 or 21 exon mutation treated Erlotinib vs…
- Trial name
- NCT01683175
- Testing
- Erlotinib, cis-platinum, Vinorelbine
- Where
- 15 sites in China
- Volunteers
- 94 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-small Cell Lung Cancer, Effects of Chemotherapy
Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients
In the National Comprehensive Cancer Network (NCCN) guideline for NSCLC, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is recommended as the third-line treatment for EGFR gene mutation negative NSCLC…
- Trial name
- NCT01749072
- Testing
- Gefitinib group, Vinorelbine, Ifosfamide, Mesna
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking Union Medical College Hospital
Breast Neoplasms
Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma
Study Objective : To assess the efficacy and the safety of the combination of Oxaliplatin, and Vinorelbine with or without Trastuzumab as a salvage regimen in patients with Metastatic Breast Cancer
- Trial name
- NCT00403988
- Testing
- Oxaliplatin, vinorelbine
- Where
- Lebanon
- Volunteers
- 40 people
- Sponsor
- American University of Beirut Medical Center
NSCLC Stage IIIA/B
Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)
Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT)
- Trial name
- NCT02118415
- Testing
- Hsp70-peptide TKD/IL-2 activated, autologous NK cells
- Where
- Germany
- Volunteers
- 13 people
- Sponsor
- Technical University of Munich
Breast Cancer
Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)
The primary objective of this study is to compare the efficacy of sacituzumab govitecan to the treatment of physician's choice (TPC) as measured by independently-reviewed Independent Review Committee (IRC) progression-free…
- Trial name
- ASCENT (NCT02574455)
- Testing
- Sacituzumab govitecan, Eribulin, Capecitabine
- Where
- 230 sites in United States, Belgium and 5 more
- Volunteers
- 529 people
- Sponsor
- Gilead Sciences
Breast Cancer
Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients
vinorelbine are one of the main chemotherapy drugs used in the treatment of advanced breast cancer. It is available in oral form, making it convenient to use and an ideal choice for rhythmic chemotherapy.
- Trial name
- NCT06015126
- Testing
- metronomic oral vinorelbine plus anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Yan Xue
Breast Cancer
Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00513058
- Testing
- Lapatinib, vinorelbine
- Where
- 5 sites in France
- Volunteers
- 33 people
- Sponsor
- UNICANCER
Breast Cancer, Cancer
Vinorelbine and XR9576 to Treat Cancer
Tumor resistance to anti-cancer drugs is a major problem in cancer treatment. Studies have found that a protein (P-glycoprotein) on some cancer cells pumps chemotherapy drugs out of the cells, reducing treatment effectiveness.
- Conditions
- Breast Cancer, Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00001944
- Testing
- Vinorelbine, XR9576
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung, Carcinoma Breast
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
This is an open-label, single-arm, Phase II investigator-initiated trial of vinorelbine metronomic chemotherapy combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for treatment of…
- Trial name
- NCT05603013
- Testing
- Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Cancer
Lapatinib in Combination With Vinorelbine
This is a Multicenter, Open-Label, Phase II Study of lapatinib in Combination with Vinorelbine in women with documented evidence of HER2/neu positive breast cancer which is metastatic or recurrent and with or without prior…
- Trial name
- NCT01128543
- Testing
- lapatinib and Vinorelbine
- Where
- 8 sites in Turkey (Türkiye)
- Volunteers
- 29 people
- Sponsor
- GlaxoSmithKline
Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
This randomized phase III trial studies how well combination chemotherapy (vincristine sulfate, dactinomycin, cyclophosphamide alternated with vincristine sulfate and irinotecan hydrochloride or vinorelbine) works compared to…
- Conditions
- Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Rhabdomyosarcoma
- Trial name
- NCT02567435
- Testing
- Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride
- Where
- 382 sites in United States, Australia and 3 more
- Volunteers
- 325 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
This study will compare the efficacy and safety of Tarceva (erlotinib) and vinorelbine in chemo-naive elderly patients with advanced non-small cell lung cancer.
- Trial name
- NCT01196078
- Testing
- erlotinib [Tarceva], vinorelbine
- Where
- Taiwan
- Volunteers
- 114 people
- Sponsor
- Hoffmann-La Roche
Metastatic Breast Cancer
Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer
Development of an active second-line treatment option for metastatic breast cancer patients previously pre-treated with anthracyclines and taxanes in neoadjuvant, adjuvant or palliative settings.
- Trial name
- NCT04143906
- Testing
- Vinorelbine, Gemcitabine, Carboplatin
- Volunteers
- 200 people
- Sponsor
- Shandong Cancer Hospital and Institute